STOP-HER2: Stopping Trastuzumab in HER2+ MBC
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Nancy U Lin, MD
Dana-Farber Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic Hospital Arizona
Phoenix, Arizona, United States
- Georgetown University Medical Center
Washington D.C., District of Columbia, United States
- Mayo Clinical Hospital Florida
Jacksonville, Florida, United States
- Dana-Farber Cancer Insitute
Boston, Massachusetts, United States
- Dfci @ Foxborough
Foxborough, Massachusetts, United States
- Dfci @ Merrimack Valley
Methuen, Massachusetts, United States
- Dfci @ Milford Regional Hospital
Milford, Massachusetts, United States
- Dfci @ South Shore Hospital
South Weymouth, Massachusetts, United States
- Mayo Clinic Rochester
Rochester, Minnesota, United States
- Duke University
Durham, North Carolina, United States
- University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
- Baylor College of Medicine
Houston, Texas, United States
- Fred Hutchinson Cancer Center
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 19 Apr 2023
- Primary completion
- 30 Jun 2026
- Completion
- 30 Jun 2036
- Last update posted
- 20 Feb 2026
- Registered enrollment
- 82
- Registry id
- NCT05721248
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.